Kumar Vinayshree, Silvis Christine, Nystrom Gerald, Deshpande Nobuko, Vary Thomas C, Frost Robert A, Lang Charles H
Department of Cellular and Molecular Phsysiology, and Surgery, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, USA.
Alcohol Clin Exp Res. 2002 Oct;26(10):1574-83. doi: 10.1097/01.ALC.0000034034.05171.4A.
Alcohol (EtOH) alters the plasma and tissue content of insulin-like growth factor (IGF)-I, an important anabolic hormone. However, the bioavailability and bioactivity of IGF-I can also be modulated by changes in soluble proteins that bind IGF-I (IGFBPs). The purpose of the present study was to determine whether EtOH intoxication in rats alters the plasma concentration and tissue mRNA content of various IGFBPs. Based on initial results subsequent studies were performed to assess potential mechanisms by which EtOH increased IGFBP-1.
Rats were administered EtOH (75 mmol/kg) and blood and tissues collected at various times thereafter. Separate groups of rats were also pretreated with 4-methylpyrazole (4-MP; alcohol dehydrogenase inhibitor), cyanamide (inhibitor of acetaldehyde metabolism), RU486 (glucocorticoid receptor antagonist) or the tumor necrosis factor (TNF) antagonist (TNF(BP)) prior to EtOH administration.
Acute EtOH intoxication did not alter the mRNA content of IGFBP-3, -4 or -5 in liver or kidney. However, EtOH increased IGFBP-1 in blood (5-fold), which was associated with an up-regulation of IGFBP-1 mRNA content in liver and kidney (2- to 3-fold). Likewise, the injection of the nonmetabolizable alcohol -butanol also increased IGFBP-1 in plasma, liver, and kidney. The increased IGFBP-1 in blood and tissues was not prevented by inhibiting alcohol metabolism with 4-MP. However, pretreatment with cyanamide markedly accentuated the EtOH-induced increase in IGFBP-1 in blood (20-fold), liver (3.5-fold), and kidney (12-fold), indicating that accumulation of acetaldehyde can enhance IGFBP-1 synthesis. A time course study indicated that EtOH increased plasma IGFBP-1 levels as early as 0.5-1 hr, and that this response was associated with elevated IGFBP-1 mRNA in liver but not kidney. Pretreatment with RU486 did not prevent or attenuate the EtOH-induced increase in IGFBP-1. However, the alcohol-induced increase in IGFBP-1 was attenuated by TNF(BP).
These data suggest that the acute alcohol-induced increase in IGFBP-1 is mediated, at least in part, by TNF and is independent of EtOH metabolism and increases in endogenous glucocorticoids.
酒精(EtOH)会改变胰岛素样生长因子(IGF)-I的血浆和组织含量,IGF-I是一种重要的合成代谢激素。然而,IGF-I的生物利用度和生物活性也可通过结合IGF-I的可溶性蛋白(IGFBPs)的变化来调节。本研究的目的是确定大鼠酒精中毒是否会改变各种IGFBPs的血浆浓度和组织mRNA含量。基于初步结果,随后进行了研究以评估酒精增加IGFBP-1的潜在机制。
给大鼠注射EtOH(75 mmol/kg),并在之后的不同时间采集血液和组织。在注射EtOH之前,还对单独的几组大鼠用4-甲基吡唑(4-MP;乙醇脱氢酶抑制剂)、氰胺(乙醛代谢抑制剂)、RU486(糖皮质激素受体拮抗剂)或肿瘤坏死因子(TNF)拮抗剂(TNF(BP))进行预处理。
急性酒精中毒并未改变肝脏或肾脏中IGFBP-3、-4或-5的mRNA含量。然而,酒精使血液中的IGFBP-1增加(5倍),这与肝脏和肾脏中IGFBP-1 mRNA含量上调(2至3倍)相关。同样,注射不可代谢的酒精——丁醇也会使血浆、肝脏和肾脏中的IGFBP-1增加。用4-MP抑制酒精代谢并不能阻止血液和组织中IGFBP-1的增加。然而,用氰胺预处理可显著增强酒精诱导的血液(20倍)、肝脏(3.5倍)和肾脏(12倍)中IGFBP-1的增加,表明乙醛的积累可增强IGFBP-1的合成。一项时间进程研究表明,酒精早在0.5 - 1小时就会使血浆IGFBP-1水平升高,且这种反应与肝脏中IGFBP-1 mRNA升高相关,但与肾脏无关。用RU486预处理并不能阻止或减弱酒精诱导的IGFBP-1增加。然而,酒精诱导的IGFBP-1增加可被TNF(BP)减弱。
这些数据表明,急性酒精诱导的IGFBP-1增加至少部分是由TNF介导的,且独立于酒精代谢和内源性糖皮质激素的增加。